中低剂量瑞舒伐他汀治疗社区高龄冠心病合并高脂血症的疗效和安全性研究

摘 要 目的：观察中低剂量瑞舒伐他汀对社区高龄冠心病合并高脂血症的疗效和安全性。方法：将2020年1月至2022年7月期间我院收治的252例社区高龄冠心病合并高脂血症患者分为中剂量组（126例）和低剂量组（126例）。中剂量组给予10 mg·d-1瑞舒伐他汀，低剂量组给予5 mg·d-1瑞舒伐他汀，比较两组患者治疗3个月、6个月后总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）和高密度脂蛋白胆固醇（HDL-C）水平，血脂达标率，以及肝肾功能指标的变化。结果：中剂量组101例完成6个月随访，低剂量组104例患者6个月随访。治疗3个月、6个月后中剂量组TC和LDL-C水平较低剂量组改善更明显（P ＜ 0.05），且高剂量组血脂达标率均高于低剂量组（P ＜ 0.05）。两组均未出现严重不良反应，且治疗前后肝肾功能各指标比较，差异无统计学意义（P ＞ 0.05）。结论：中低剂量瑞舒伐他汀治疗社区高龄冠心病合并高脂血症的安全性均良好，但中剂量（10 mg·d-1）给药可使患者血清TC和LDL-C水平下降更为明显。

Study on the Efficacy and Safety of Medium and Low Dose Rosuvastatin in the Treatment of Community Elderly Patients with Coronary Heart Disease and Hyperlipidemia

Objective: To analyze and compare the efficacy and safety of low and medium doses of rosuvastatin in community treatment of elderly hyperlipidemia. Methods: A total of 252 elderly patients with coronary heart disease and hyperlipidemia admitted to our hospital from January 2020 to July 2022 were divided into medium dose group (126 cases) and low dose group (126 cases). Patients in the medium dose group were treated with 10 mg·d-1 rosuvastatin, while those in the low dose group were treated with 5 mg·d-1 rosuvastatin. The total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels, blood lipid compliance rates, and changes in liver and kidney function indicators were compared between the two groups after 3 and 6 months of treatment. Results: After 3 and 6 months of treatment, the TC and LDL-C levels in the medium dose group improved more significantly comparing with those in the low dose group (P < 0.05), and the blood lipid compliance rate of the medium dose group was higher than that of the low dose group (P < 0.05). There were no serious adverse reactions in both groups, and there was no statistically significant difference in liver and kidney function indicators between the two groups before and after treatment (P > 0.05). Conclusions: The treatment of medium or low dose rosuvastatin is safe in community elderly coronary heart disease with hyperlipidemia, but the medium dose (10 mg·d-1) administration can cause a more significant decrease in serum TC and LDL-C levels in patients